Major Lung Cancer Trials:

1
Major Lung Cancer Trials Relative Benefits and
Risks vs. Control Arm
PFS OS Adverse events Significant activity Quality of Life
SATURN Erlotinib vs. placebo HR 0.71, Plt0.0001 analysis on-going rash, diarrhea across all subgroups maintained
ATLAS Erlotinib/bevacizumab vs. bevacizumab HR 0.72, P0.0012 analysis on-going rash, diarrhea across all subgroups N/A
Pemetrexed (vs. placebo) HR 0.60, Plt0.0001 HR 0.79, P0.012 fatigue, neutropenia in non-squamous disease N/A
Mostly in non-squamous disease HR 0.47, Plt0.00001. Mostly in non-squamous disease HR 0.47, Plt0.00001. Mostly in non-squamous disease HR 0.47, Plt0.00001. Mostly in non-squamous disease HR 0.47, Plt0.00001. Mostly in non-squamous disease HR 0.47, Plt0.00001. Mostly in non-squamous disease HR 0.47, Plt0.00001.